Interviewed payers in the US and five major EU markets (France, Germany, Italy, Spain and the UK) express concern surrounding the significant and rising cost of prostate cancer treatment. Payers highlight the large and growing epidemiology of the disease, as well as the rising costs associated with the use of expensive novel anti-androgens in earlier treatment lines.

This Datamonitor Healthcare report contains a Pricing & Reimbursement module.